HPV prevalence in British Columbia
HPV Prevalence in British Columbia
It is well established that infection with a high risk genotype of HPV is necessary for cervical cancer to develop. In 2008, HPV vaccination began in British Columbia schools. To determine the efficacy of the vaccine and to determine if there are HPV type replacements and/or cross-protection against non-vaccine HPV types in the population, an assessment of HPV subtypes in BC women in this "post-vaccination era" is required.
Additionally, there is no data on HPV genotype distribution in cervical cancer cases in British Columbia, and little for Canada. Evaluation of HPV genotype distribution in a cohort of invasive cervical cancer cervical cases in BC will allow identification of differences in HPV types between screened and unscreened women. This important information will enable estimates of the incremental impact of HPV vaccination on cervical cancer in screened women. As the BC Cervical Cancer Screening Program (CCSP) considers a shift from cytology to HPV based screening, HPV typing data will provide crucial information for program planning.